The ACCP PBRN is proud to announce the launch of the Oncology Drug Shortage Study for ACCP PBRN members who specialize in hematology/oncology. The objective of this study is to determine the impact of cytarabine shortage on the timing, dose, or chemotherapy drug regimen selection for adult patients with acute myeloid leukemia (AML), particularly minority patients with AML, relative to a non-shortage period. Cytarabine is the focus of this research study because shortage of this agent may affect life expectancy, and documented shortage has been widespread.

We invite eligible ACCP PBRN members who practice within the inpatient hematology/oncology specialty area to consider participating in this retrospective data collection research study. The study protocol, central IRB approval letter, data collection tools, and training materials are loaded under step 4 within PBRNConnect: http://www.accpri.org/signin/index.aspx. This study will use the REDCap Web-based electronic data capture tool. For more information, contact us at [email protected].

All ACCP members are welcome to join the ACCP PBRN at no cost. To be eligible to participate in PBRN projects, members must complete online portfolios within PBRNConnect. If you are already an ACCP member but have not completed your portfolio within PBRNConnect, you may do so at http://www.accpri.org/signin/index.aspx.